Global Vision's Text Comparison Software Docu-Proof Recognized By The EMA For Regulatory Submissions
Global Vision, the industry leader in the development of automated proofreading solutions, recently announced that Docu-Proof has met compliance requirements as a text comparison software solution by the European Medicines Agency (EMA) for pharmaceutical companies using parallel distribution methods of medicinal products.
Study Shows Whole-Cell Vaccine Was More Effective Than Acellular Vaccine During California Pertussis Outbreak
Whole-cell pertussis vaccines were more effective at protecting against pertussis than acellular pertussis vaccines during a large recent outbreak, according to a new Kaiser Permanente study published in Pediatrics.
The Start-Up Elsalys Biotech, A New Player In The Therapeutic Monoclonal Antibody Arena, Announces The First Round Of Financing With Transgene And Sofimac Partners
ElsaLys Biotech, which specializes in the development of therapeutic monoclonal antibodies, announces a first round of financing of 2.1M€ from the biopharmaceutical company Transgene and the investment fund Sofimac Partners.
Seminars, Technology Highlight CYTO 2013 Offerings From Beckman Coulter Life Sciences
Presenting two seminars and seven poster sessions, Beckman Coulter Life Sciences will have a prominent role when CYTO 2013 convenes at the San Diego Convention Center May 18-22, 2013.
MultiCell Technologies Files U.S. Patent Application For Targeted Delivery Of Noncoding Micro RNAs For The Treatment Of Liver Cancer
MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) is pleased to announce the filing of a U.S. patent application concerning methods and formulations to achieve targeted tumor cell death. MCT-485 is a noncoding double stranded micro RNA (miRNA) which has demonstrated oncolytic and immune stimulating activity in in vitro models of hepatocellular carcinoma.
AbbVie To Present Data On Investigational Anti-Cancer Compounds At American Society Of Clinical Oncology Annual Meeting
AbbVie (NYSE: ABBV) today announced that data evaluating several investigational compounds in the company's oncology pipeline will be presented at the upcoming 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 - June 4, Chicago.
ILC Dover Receives ISO Class 7 Cleanroom Certification
ILC Dover, the designer and manufacturer of NASA’s space suits and a wide range of engineered film and fabric products, announced recently it has received certification for its ISO Class 7 Clean Room.
Global Vision Selected By Pfizer For Worldwide Deployment Of Automated Proofreading Solutions
Global Vision, the industry leader in the development of automated proofreading solutions, recently announced that it has been selected by Pfizer for worldwide deployment as its proofreading technology solution provider.
NanoPass Technologies Supports A CDC-Sponsored Phase 3 Study Of Polio Vaccine In Infants As Part Of its Global Health Initiative
NanoPass Technologies Ltd. ("NanoPass"), a pioneer in intradermal (into-the-skin or ID) vaccine delivery solutions, is collaborating with the US Center of Disease Control and prevention (CDC) in conducting a large phase 3 trial of polio vaccine in infants in South East Asia.
U.S. FDA Grants Priority Review To Simeprevir (TMC435) For Combination Treatment Of Genotype 1 Chronic Hepatitis C
Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for simeprevir (TMC435), an investigational NS3/4A protease inhibitor administered as a 150 mg capsule once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease.